MA-ICURE-PHARMACEUTICAL
16.11.2021 15:03:14 CET | Business Wire | Press release
Icure Pharmaceutical Inc. (KOSDAQ: 175250), a biopharmaceutical company in Korea, announced today that its donepezil patch, a treatment of Alzheimer’s-type dementia, received a drug product approval from the Ministry of Food and Drug Safety of Korea.
The drug product approval process took 7 months after it filed an application in April 2021. With the approval, Icure marks the first commercialization of the donepezil patch in the world.
Donepezil is a current typical treatment that has been widely prescribed for the longest period for Alzheimer’s disease patients in severity ranging from mild to moderate and severe ones among FDA-approved Alzheimer's treatments. Due to difficulty in the development of its formulations, donepezil has been commercialized for only oral administration to date.
With successful completion of a Phase III clinical trial for the first time in the world, the donepezil patch of Icure is expected to significantly improve the quality of life of patients with Alzheimer’s-type dementia and their caregivers by enhancing the convenience in its use from orally taking once daily to putting a patch on skin twice a week.
With nearly 400 mild and moderate dementia patients in Korea, Taiwan, Australia and Malaysia, Icure successfully conducted a Phase III clinical study for its donepezil patch. Specifically, the study demonstrated noninferiority compared to oral donepezil in Alzheimer's disease assessment scale cognitive subscale (ADAS-cog), a typical standard tool for evaluating abilities of memory, language, reorganization, action and orientation in patients with mild and moderate Alzheimer’s-type dementia.
“Based on outstanding efficacy and marketability of donepezil along with our technological prowess, we expect our donepezil patch will sufficiently take over the market of donepezil oral products as we have seen a high conversion rate of rivastigmine patches in the past,” said CEO YoungKweon Choi, Ph.D. of Icure, who led donepezil patch development. “We reported results of the Phase III clinical trial of donepezil patch at the Conference on Clinical Trials of Alzheimer’s Disease (CTAD) that was held on November 9~12, 2021 in Boston, Massachusetts.” He attended the CTAD Conference to present the results of the clinical study while making consultations on potential global transactions.
Now that its donepezil patch received FDA approval for Phase I clinical trial as an investigational new drug in April 2021, Icure will start to administer it to patients in the latter part of 2022. The company expects to begin in 2025 to provide the donepezil patch in the global market by reducing the period of clinical trials through the 505(b)2 clinical study track. Today, the global dementia treatments market is estimated to reach around USD 3 billion, and it is anticipated to increase to roughly USD 5 billion by 2024 as the world transforms into an aging society. Icure plans to expand the global business of transdermal drug delivery system (TDDS) as its production facilities in Wanju, Korea obtained the cGMP certification.
Starting with the donepezil patch, Icure diversifies pipelines by developing a variety of DDS-based incrementally modified drugs and new drugs. Following the donepezil patch, the company is developing a pramipexole patch that will be used for treating Parkinson’s disease. And Icure BNP, a subsidiary of Icure, is currently developing oral liraglutide peptide formulation from injectable liraglutide peptide product that is being used for treating diabetes and obesity while accelerating the development of microneedles and lipid-based nanoparticle (LNP) drugs through CuRsuS Bio and EBA BIO. In addition, Icure is also in the development of the world’s first oral peptide-based anticancer drug and a new drug based on PROTAC through oneCureGen and Dandi Cure, attracting attention on the potentiality of growing into a global pharmaceutical company by developing varied DDS-based new drugs.
For more information on Icure Pharmaceutical Inc., visit https://icure.co.kr .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005684/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates5.8.2026 12:00:00 CEST | Press release
Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior yearDiluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarterRaised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “These strong second-quarter results underscore our continued growth as a global oncology leader. Our foundational hematology franchise, led by BRUKINSA, continues to gain momentum as we advance one of the industry’s deepest and most
Tecnotree Delivers Double-Digit Profit Growth and Accelerated Deployment Momentum in H1 20265.8.2026 11:11:00 CEST | Press release
Tecnotree, a global leader in AI-native Digital Business Support Systems (BSS) and digital platform solutions for the telecommunications industry, today announced its financial results for the first half of 2026. The company delivered growth across every principal financial measure, expanded operating margin by 800 basis points, and converted a record order book into deployment at pace, with eight go-lives completed across the North America, Africa and the Middle East. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805406933/en/ Tecnotree Delivers Double-Digit Profit Growth and Accelerated Deployment Momentum in H1 2026 First Half (January – June 2026) Net sales of EUR 36.8 million (EUR 34.2 million), up 7.5% year-on-year; in constant currency, EUR 37.6 million, up 10.0% year-on-year. Operating result (EBIT) of EUR 13.2 million (EUR 9.6 million), up 38.1% year-on-year. Operating margin of 36.0% (28.0%), up 800 bps year-on
Ekovolt Welcomes Éric Scotto, Co-Founder of Akuo Energy, as a Shareholder, and Rebrands as Pont Digital Infrastructure5.8.2026 10:00:00 CEST | Press release
Ekovolt, a holding company focused on the development and investment in next-generation data centre infrastructure, and co-owner of Voltekko, a Southern European data centre development platform, today announces two milestones: Éric Scotto — co-founder and former President of Akuo Energy, a pioneering figure in the French and international energy transition — becoming a shareholder, and the company’s rebranding as Pont Digital Infrastructure. Éric Scotto, an iconic figure in French renewable energy, joins the company as a shareholder, bringing recognised expertise in developing, financing and structuring long-term sustainable infrastructure projects. After an early career in information technology and finance, Éric Scotto moved into renewable energy in 2003. He founded Perfect Wind and developed one of the first large-scale wind farms in France (57 MW) in partnership with General Electric — with operations also in Poland and Turkey — before selling the company to Iberdrola in 2006. In
Bending Spoons opens office in Madrid, betting on a promising pool of tech talent5.8.2026 09:00:00 CEST | Press release
Bending Spoons, the technology company behind products such as WeTransfer and Meetup, has opened an office in Madrid. The decision is underpinned by Spain’s strong talent pool, fuelled by excellent universities, and by Madrid’s international appeal and its quality of life. “We’re impressed by the talent we’ve seen in Spain. This year, we’ve received around 10,000 Spain-based applicants every month, and many of them perform among the very best candidates in our selection process. The calibre of education offered by Spanish universities is particularly high, and over the next few years we’re hoping to grow our team in Madrid into the hundreds,” says Andrea Maiorana, talent data lead. Located in the Recoletos area, the office is the company’s third European base, following the Milan headquarters and the recently opened London branch. The office is in one of the city's most coveted locations, within walking distance of Retiro Park and the Prado Museum. For new hires relocating to Madrid, B
Moove Raises $250 Million at $2.1 Billion Valuation to Scale the Global Infrastructure Layer for Autonomous Mobility5.8.2026 09:00:00 CEST | Press release
Led by Mubadala Investment Company "Mubadala", and co-led by Woven Capital (Toyota) and Ion Pacific, the Series C accelerates Moove’s global infrastructure platform for autonomous mobility as the market shifts from breakthrough technology to scaled deployment.$250 million Series C values Moove at $2.1 billion, cementing its position as the category defining infrastructure company for the autonomous mobility economyMoove is building the core operating layer for autonomous mobility globally through integrated fleet management, robotics-first depot infrastructure, and 24/7 operationsThrough its partnership with Waymo, Moove is already a leading third-party autonomous vehicle fleet manager, with operations live or announced across Phoenix, Miami and LondonMoove’s autonomous strategy is grounded in five years of building and operating mobility infrastructure at scale, from an initial launch of 76 vehicles in Lagos to approximately 42,000 vehicles across 29 cities (13 countries) and achievin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom